Salmeterol superfine formulation
US8088362B2 · kind B2 · utility
2Cited by
9References
30Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 18, 2003 |
| Grant date | Jan 3, 2012 |
| Priority date | — |
| Expiry date | May 31, 2028 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P11/08
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a pharmaceutical formulation for use in the administration of a long-acting β2-agonist by inhalation. In particular this invention relates to a chemically stable, highly efficient salmeterol HFA solution formulation to be administered by pressurized metered dose inhalers (pMDIs) characterized by a deep lung penetration. The invention also relates to methods for the preparation of said formulation and to its use in respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.